Clinical Cancer Research · 2020 · 69 citations · 42 references
These studies demonstrate that APOBEC3B is overexpressed in a subset of CCOC and, contrary to initial expectations, associated with improved (not worse) clinical outcomes. A likely molecular explanation is that APOBEC3B-induced DNA damage sensitizes cells to additional genotoxic stress by cisplatin. Thus, APOBEC3B is a molecular determinant and a candidate predictive biomarker of the therapeutic response to platinum-based chemotherapy. These findings may have broader translational relevance, as APOBEC3B is overexpressed in many different cancer types.
42
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Wendy Winckler · Nature · 2011 · 8K citations · Full text
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke, Rileen Sinha, Douglas A. Levine et al. · Nature Communications · 2013 · 1.4K citations · Full text
APOBEC3B is an enzymatic source of mutation in breast cancer
Michael B. Burns, Lela Lackey, Michael A. Carpenter et al. · Nature · 2013 · 864 citations · Full text